Nuclear Medicine and Radiopharmaceuticals Market Report

1. Global Nuclear Medicine and Radiopharmaceuticals Executive Summary

• 1.1 Introduction

• 1.2 Market Panorama, 2022

2 Coronavirus Impact

• 2.1 Nuclear Medicine and Radiopharmaceuticals Outlook to 2028- Original Forecasts

• 2.2 Nuclear Medicine and Radiopharmaceuticals Outlook to 2028- COVID-19 Affected Forecasts

• 2.3 Impact on Industry

3 Strategic Analytics to Boost Productivity and Profitability

• 3.1 Potential Market Drivers and Opportunities

• 3.2 New Challenges and Strategies

• 3.3 Short Term and Long Term Nuclear Medicine and Radiopharmaceuticals Market Trends

4 Key Inferences

5 Market Overview

• 5.1 Current Market Scenario

• 5.2 Porter's Five Forces Analysis

• 5.2.1 Bargaining Power of Suppliers

• 5.2.2 Bargaining Power of Consumers

• 5.2.3 Threat of New Entrants

• 5.2.4 Threat of Substitute Product and Services

• 5.2.5 Competitive Rivalry within the Industry

6 Global Nuclear Medicine and Radiopharmaceuticals Market- Recent Developments

• 6.1 Nuclear Medicine and Radiopharmaceuticals Market News and Developments

• 6.2 Nuclear Medicine and Radiopharmaceuticals Market Deals Landscape

7 Nuclear Medicine and Radiopharmaceuticals Raw Materials and Cost Structure Analysis

• 7.1 Nuclear Medicine and Radiopharmaceuticals Key Raw Materials

• 7.2 Nuclear Medicine and Radiopharmaceuticals Price Trend of Key Raw Materials

• 7.3 Nuclear Medicine and Radiopharmaceuticals Key Suppliers of Raw Materials

• 7.4 Nuclear Medicine and Radiopharmaceuticals Market Concentration Rate of Raw Materials

• 7.5 Nuclear Medicine and Radiopharmaceuticals Cost Structure Analysis

• 7.5.1 Nuclear Medicine and Radiopharmaceuticals Raw Materials Analysis

• 7.5.2 Nuclear Medicine and Radiopharmaceuticals Labor Cost Analysis

• 7.5.3 Nuclear Medicine and Radiopharmaceuticals Manufacturing Expenses Analysis

8 Global Nuclear Medicine and Radiopharmaceuticals Import and Export Analysis (Top 10 Countries)

• 8.1 Global Nuclear Medicine and Radiopharmaceuticals Import by Region (Top 10 Countries) (2017-2028)

• 8.2 Global Nuclear Medicine and Radiopharmaceuticals Export by Region (Top 10 Countries) (2017-2028)

9 Global Nuclear Medicine and Radiopharmaceuticals Market Outlook by Types and Applications to 2022

• 9.1 Global Nuclear Medicine and Radiopharmaceuticals Consumption and Growth Rate by Type (2017-2022)

• 9.1.1 Global Diagnostic Radioisotopes Consumption and Growth Rate (2017-2022)

• 9.1.2 Global Therapeutic Radioisotopes Consumption and Growth Rate (2017-2022)

• 9.2 Global Nuclear Medicine and Radiopharmaceuticals Consumption and Growth Rate by Application (2017-2022)

• 9.2.1 Global Oncology Consumption and Growth Rate (2017-2022)

• 9.2.2 Global Cardiology Consumption and Growth Rate (2017-2022)

• 9.2.3 Global Other Consumption and Growth Rate (2017-2022)

10 Region and Country-wise Nuclear Medicine and Radiopharmaceuticals Market Analysis and Outlook till 2022

• 10.1 Global Nuclear Medicine and Radiopharmaceuticals Consumption (2017-2022)

• 10.2 North America Consumption Analysis

• 10.2.1 United States Nuclear Medicine and Radiopharmaceuticals Consumption (2017-2022)

• 10.2.2 Canada Nuclear Medicine and Radiopharmaceuticals Consumption (2017-2022)

• 10.2.3 Mexico Nuclear Medicine and Radiopharmaceuticals Consumption (2017-2022)

• 10.3 Europe Consumption Analysis

• 10.3.1 Germany Nuclear Medicine and Radiopharmaceuticals Consumption (2017-2022)

• 10.3.2 UK Nuclear Medicine and Radiopharmaceuticals Consumption (2017-2022)

• 10.3.3 Spain Nuclear Medicine and Radiopharmaceuticals Consumption (2017-2022)

• 10.3.4 Belgium Nuclear Medicine and Radiopharmaceuticals Consumption (2017-2022)

• 10.3.5 France Nuclear Medicine and Radiopharmaceuticals Consumption (2017-2022)

• 10.3.6 Italy Nuclear Medicine and Radiopharmaceuticals Consumption (2017-2022)

• 10.3.7 Denmark Nuclear Medicine and Radiopharmaceuticals Consumption (2017-2022)

• 10.3.8 Finland Nuclear Medicine and Radiopharmaceuticals Consumption (2017-2022)

• 10.3.9 Norway Nuclear Medicine and Radiopharmaceuticals Consumption (2017-2022)

• 10.3.10 Sweden Nuclear Medicine and Radiopharmaceuticals Consumption (2017-2022)

• 10.3.11 Poland Nuclear Medicine and Radiopharmaceuticals Consumption (2017-2022)

• 10.3.12 Russia Nuclear Medicine and Radiopharmaceuticals Consumption (2017-2022)

• 10.3.13 Turkey Nuclear Medicine and Radiopharmaceuticals Consumption (2017-2022)

• 10.4 APAC Consumption Analysis

• 10.4.1 China Nuclear Medicine and Radiopharmaceuticals Consumption (2017-2022)

• 10.4.2 Japan Nuclear Medicine and Radiopharmaceuticals Consumption (2017-2022)

• 10.4.3 India Nuclear Medicine and Radiopharmaceuticals Consumption (2017-2022)

• 10.4.4 South Korea Nuclear Medicine and Radiopharmaceuticals Consumption (2017-2022)

• 10.4.5 Pakistan Nuclear Medicine and Radiopharmaceuticals Consumption (2017-2022)

• 10.4.6 Bangladesh Nuclear Medicine and Radiopharmaceuticals Consumption (2017-2022)

• 10.4.7 Indonesia Nuclear Medicine and Radiopharmaceuticals Consumption (2017-2022)

• 10.4.8 Thailand Nuclear Medicine and Radiopharmaceuticals Consumption (2017-2022)

• 10.4.9 Singapore Nuclear Medicine and Radiopharmaceuticals Consumption (2017-2022)

• 10.4.10 Malaysia Nuclear Medicine and Radiopharmaceuticals Consumption (2017-2022)

• 10.4.11 Philippines Nuclear Medicine and Radiopharmaceuticals Consumption (2017-2022)

• 10.4.12 Vietnam Nuclear Medicine and Radiopharmaceuticals Consumption (2017-2022)

• 10.5 South America Consumption Analysis

• 10.5.1 Brazil Nuclear Medicine and Radiopharmaceuticals Consumption (2017-2022)

• 10.5.2 Colombia Nuclear Medicine and Radiopharmaceuticals Consumption (2017-2022)

• 10.5.3 Chile Nuclear Medicine and Radiopharmaceuticals Consumption (2017-2022)

• 10.5.4 Argentina Nuclear Medicine and Radiopharmaceuticals Consumption (2017-2022)

• 10.5.5 Venezuela Nuclear Medicine and Radiopharmaceuticals Consumption (2017-2022)

• 10.5.6 Peru Nuclear Medicine and Radiopharmaceuticals Consumption (2017-2022)

• 10.5.7 Puerto Rico Nuclear Medicine and Radiopharmaceuticals Consumption (2017-2022)

• 10.5.8 Ecuador Nuclear Medicine and Radiopharmaceuticals Consumption (2017-2022)

• 10.6 GCC Consumption Analysis

• 10.6.1 Bahrain Nuclear Medicine and Radiopharmaceuticals Consumption (2017-2022)

• 10.6.2 Kuwait Nuclear Medicine and Radiopharmaceuticals Consumption (2017-2022)

• 10.6.3 Oman Nuclear Medicine and Radiopharmaceuticals Consumption (2017-2022)

• 10.6.4 Qatar Nuclear Medicine and Radiopharmaceuticals Consumption (2017-2022)

• 10.6.5 Saudi Arabia Nuclear Medicine and Radiopharmaceuticals Consumption (2017-2022)

• 10.6.6 United Arab Emirates Nuclear Medicine and Radiopharmaceuticals Consumption (2017-2022)

• 10.7 Africa Consumption Analysis

• 10.7.1 Nigeria Nuclear Medicine and Radiopharmaceuticals Consumption (2017-2022)

• 10.7.2 South Africa Nuclear Medicine and Radiopharmaceuticals Consumption (2017-2022)

• 10.7.3 Egypt Nuclear Medicine and Radiopharmaceuticals Consumption (2017-2022)

• 10.7.4 Algeria Nuclear Medicine and Radiopharmaceuticals Consumption (2017-2022)

• 10.8 Oceania Consumption Analysis

• 10.8.1 Australia Nuclear Medicine and Radiopharmaceuticals Consumption (2017-2022)

• 10.8.2 New Zealand Nuclear Medicine and Radiopharmaceuticals Consumption (2017-2022)

11 Global Nuclear Medicine and Radiopharmaceuticals Competitive Analysis

• 11.1 Navidea

• 11.1.1 Navidea Company Details

• 11.1.2 Navidea Nuclear Medicine and Radiopharmaceuticals Sales, Price, Value and Gross Profit (2017-2022)

• 11.1.3 Navidea Nuclear Medicine and Radiopharmaceuticals Main Business and Markets Served

• 11.1.4 Navidea Nuclear Medicine and Radiopharmaceuticals Product Portfolio

• 11.1.5 Recent Research and Development Strategies

• 11.2 Mallinckrodt

• 11.2.1 Mallinckrodt Company Details

• 11.2.2 Mallinckrodt Nuclear Medicine and Radiopharmaceuticals Sales, Price, Value and Gross Profit (2017-2022)

• 11.2.3 Mallinckrodt Nuclear Medicine and Radiopharmaceuticals Main Business and Markets Served

• 11.2.4 Mallinckrodt Nuclear Medicine and Radiopharmaceuticals Product Portfolio

• 11.2.5 Recent Research and Development Strategies

• 11.3 Dongcheng

• 11.3.1 Dongcheng Company Details

• 11.3.2 Dongcheng Nuclear Medicine and Radiopharmaceuticals Sales, Price, Value and Gross Profit (2017-2022)

• 11.3.3 Dongcheng Nuclear Medicine and Radiopharmaceuticals Main Business and Markets Served

• 11.3.4 Dongcheng Nuclear Medicine and Radiopharmaceuticals Product Portfolio

• 11.3.5 Recent Research and Development Strategies

• 11.4 Triad Isotopes

• 11.4.1 Triad Isotopes Company Details

• 11.4.2 Triad Isotopes Nuclear Medicine and Radiopharmaceuticals Sales, Price, Value and Gross Profit (2017-2022)

• 11.4.3 Triad Isotopes Nuclear Medicine and Radiopharmaceuticals Main Business and Markets Served

• 11.4.4 Triad Isotopes Nuclear Medicine and Radiopharmaceuticals Product Portfolio

• 11.4.5 Recent Research and Development Strategies

• 11.5 Lantheus

• 11.5.1 Lantheus Company Details

• 11.5.2 Lantheus Nuclear Medicine and Radiopharmaceuticals Sales, Price, Value and Gross Profit (2017-2022)

• 11.5.3 Lantheus Nuclear Medicine and Radiopharmaceuticals Main Business and Markets Served

• 11.5.4 Lantheus Nuclear Medicine and Radiopharmaceuticals Product Portfolio

• 11.5.5 Recent Research and Development Strategies

• 11.6 Advanced Accelerator Applications

• 11.6.1 Advanced Accelerator Applications Company Details

• 11.6.2 Advanced Accelerator Applications Nuclear Medicine and Radiopharmaceuticals Sales, Price, Value and Gross Profit (2017-2022)

• 11.6.3 Advanced Accelerator Applications Nuclear Medicine and Radiopharmaceuticals Main Business and Markets Served

• 11.6.4 Advanced Accelerator Applications Nuclear Medicine and Radiopharmaceuticals Product Portfolio

• 11.6.5 Recent Research and Development Strategies

• 11.7 Bayer

• 11.7.1 Bayer Company Details

• 11.7.2 Bayer Nuclear Medicine and Radiopharmaceuticals Sales, Price, Value and Gross Profit (2017-2022)

• 11.7.3 Bayer Nuclear Medicine and Radiopharmaceuticals Main Business and Markets Served

• 11.7.4 Bayer Nuclear Medicine and Radiopharmaceuticals Product Portfolio

• 11.7.5 Recent Research and Development Strategies

• 11.8 Bracco Imaging

• 11.8.1 Bracco Imaging Company Details

• 11.8.2 Bracco Imaging Nuclear Medicine and Radiopharmaceuticals Sales, Price, Value and Gross Profit (2017-2022)

• 11.8.3 Bracco Imaging Nuclear Medicine and Radiopharmaceuticals Main Business and Markets Served

• 11.8.4 Bracco Imaging Nuclear Medicine and Radiopharmaceuticals Product Portfolio

• 11.8.5 Recent Research and Development Strategies

• 11.9 Nordion

• 11.9.1 Nordion Company Details

• 11.9.2 Nordion Nuclear Medicine and Radiopharmaceuticals Sales, Price, Value and Gross Profit (2017-2022)

• 11.9.3 Nordion Nuclear Medicine and Radiopharmaceuticals Main Business and Markets Served

• 11.9.4 Nordion Nuclear Medicine and Radiopharmaceuticals Product Portfolio

• 11.9.5 Recent Research and Development Strategies

• 11.10 GE Healthcare

• 11.10.1 GE Healthcare Company Details

• 11.10.2 GE Healthcare Nuclear Medicine and Radiopharmaceuticals Sales, Price, Value and Gross Profit (2017-2022)

• 11.10.3 GE Healthcare Nuclear Medicine and Radiopharmaceuticals Main Business and Markets Served

• 11.10.4 GE Healthcare Nuclear Medicine and Radiopharmaceuticals Product Portfolio

• 11.10.5 Recent Research and Development Strategies

• 11.11 SIEMENS

• 11.11.1 SIEMENS Company Details

• 11.11.2 SIEMENS Nuclear Medicine and Radiopharmaceuticals Sales, Price, Value and Gross Profit (2017-2022)

• 11.11.3 SIEMENS Nuclear Medicine and Radiopharmaceuticals Main Business and Markets Served

• 11.11.4 SIEMENS Nuclear Medicine and Radiopharmaceuticals Product Portfolio

• 11.11.5 Recent Research and Development Strategies

• 11.12 IBA Group

• 11.12.1 IBA Group Company Details

• 11.12.2 IBA Group Nuclear Medicine and Radiopharmaceuticals Sales, Price, Value and Gross Profit (2017-2022)

• 11.12.3 IBA Group Nuclear Medicine and Radiopharmaceuticals Main Business and Markets Served

• 11.12.4 IBA Group Nuclear Medicine and Radiopharmaceuticals Product Portfolio

• 11.12.5 Recent Research and Development Strategies

• 11.13 Eli Lilly

• 11.13.1 Eli Lilly Company Details

• 11.13.2 Eli Lilly Nuclear Medicine and Radiopharmaceuticals Sales, Price, Value and Gross Profit (2017-2022)

• 11.13.3 Eli Lilly Nuclear Medicine and Radiopharmaceuticals Main Business and Markets Served

• 11.13.4 Eli Lilly Nuclear Medicine and Radiopharmaceuticals Product Portfolio

• 11.13.5 Recent Research and Development Strategies

• 11.14 China Isotope & Radiation

• 11.14.1 China Isotope & Radiation Company Details

• 11.14.2 China Isotope & Radiation Nuclear Medicine and Radiopharmaceuticals Sales, Price, Value and Gross Profit (2017-2022)

• 11.14.3 China Isotope & Radiation Nuclear Medicine and Radiopharmaceuticals Main Business and Markets Served

• 11.14.4 China Isotope & Radiation Nuclear Medicine and Radiopharmaceuticals Product Portfolio

• 11.14.5 Recent Research and Development Strategies

• 11.15 Jubilant Pharma

• 11.15.1 Jubilant Pharma Company Details

• 11.15.2 Jubilant Pharma Nuclear Medicine and Radiopharmaceuticals Sales, Price, Value and Gross Profit (2017-2022)

• 11.15.3 Jubilant Pharma Nuclear Medicine and Radiopharmaceuticals Main Business and Markets Served

• 11.15.4 Jubilant Pharma Nuclear Medicine and Radiopharmaceuticals Product Portfolio

• 11.15.5 Recent Research and Development Strategies

12 Global Nuclear Medicine and Radiopharmaceuticals Market Outlook by Types and Applications to 2028

• 12.1 Global Nuclear Medicine and Radiopharmaceuticals Consumption Forecast and Growth Rate by Type (2022-2028)

• 12.1.1 Global Diagnostic Radioisotopes Consumption Forecast and Growth Rate (2022-2028)

• 12.1.2 Global Therapeutic Radioisotopes Consumption Forecast and Growth Rate (2022-2028)

• 12.2 Global Nuclear Medicine and Radiopharmaceuticals Consumption Forecast and Growth Rate by Application (2022-2028)

• 12.2.1 Global Oncology Consumption Forecast and Growth Rate (2022-2028)

• 12.2.2 Global Cardiology Consumption Forecast and Growth Rate (2022-2028)

• 12.2.3 Global Other Consumption Forecast and Growth Rate (2022-2028)

13 Country-wise Nuclear Medicine and Radiopharmaceuticals Market Analysis and Outlook to 2028

• 13.1 Global Nuclear Medicine and Radiopharmaceuticals Consumption Forecast (2022-2028)

• 13.2 North America Consumption Analysis

• 13.2.1 United States Nuclear Medicine and Radiopharmaceuticals Consumption Forecast (2022-2028)

• 13.2.2 Canada Nuclear Medicine and Radiopharmaceuticals Consumption Forecast (2022-2028)

• 13.2.3 Mexico Nuclear Medicine and Radiopharmaceuticals Consumption Forecast (2022-2028)

• 13.3 Europe Consumption Analysis

• 13.3.1 Germany Nuclear Medicine and Radiopharmaceuticals Consumption Forecast (2022-2028)

• 13.3.2 UK Nuclear Medicine and Radiopharmaceuticals Consumption Forecast (2022-2028)

• 13.3.3 Spain Nuclear Medicine and Radiopharmaceuticals Consumption Forecast (2022-2028)

• 13.3.4 Belgium Nuclear Medicine and Radiopharmaceuticals Consumption Forecast (2022-2028)

• 13.3.5 France Nuclear Medicine and Radiopharmaceuticals Consumption Forecast (2022-2028)

• 13.3.6 Italy Nuclear Medicine and Radiopharmaceuticals Consumption Forecast (2022-2028)

• 13.3.7 Denmark Nuclear Medicine and Radiopharmaceuticals Consumption Forecast (2022-2028)

• 13.3.8 Finland Nuclear Medicine and Radiopharmaceuticals Consumption Forecast (2022-2028)

• 13.3.9 Norway Nuclear Medicine and Radiopharmaceuticals Consumption Forecast (2022-2028)

• 13.3.10 Sweden Nuclear Medicine and Radiopharmaceuticals Consumption Forecast (2022-2028)

• 13.3.11 Poland Nuclear Medicine and Radiopharmaceuticals Consumption Forecast (2022-2028)

• 13.3.12 Russia Nuclear Medicine and Radiopharmaceuticals Consumption Forecast (2022-2028)

• 13.3.13 Turkey Nuclear Medicine and Radiopharmaceuticals Consumption Forecast (2022-2028)

• 13.4 APAC Consumption Analysis

• 13.4.1 China Nuclear Medicine and Radiopharmaceuticals Consumption Forecast (2022-2028)

• 13.4.2 Japan Nuclear Medicine and Radiopharmaceuticals Consumption Forecast (2022-2028)

• 13.4.3 India Nuclear Medicine and Radiopharmaceuticals Consumption Forecast (2022-2028)

• 13.4.4 South Korea Nuclear Medicine and Radiopharmaceuticals Consumption Forecast (2022-2028)

• 13.4.5 Pakistan Nuclear Medicine and Radiopharmaceuticals Consumption Forecast (2022-2028)

• 13.4.6 Bangladesh Nuclear Medicine and Radiopharmaceuticals Consumption Forecast (2022-2028)

• 13.4.7 Indonesia Nuclear Medicine and Radiopharmaceuticals Consumption Forecast (2022-2028)

• 13.4.8 Thailand Nuclear Medicine and Radiopharmaceuticals Consumption Forecast (2022-2028)

• 13.4.9 Singapore Nuclear Medicine and Radiopharmaceuticals Consumption Forecast (2022-2028)

• 13.4.10 Malaysia Nuclear Medicine and Radiopharmaceuticals Consumption Forecast (2022-2028)

• 13.4.11 Philippines Nuclear Medicine and Radiopharmaceuticals Consumption Forecast (2022-2028)

• 13.4.12 Vietnam Nuclear Medicine and Radiopharmaceuticals Consumption Forecast (2022-2028)

• 13.5 South America Consumption Analysis

• 13.5.1 Brazil Nuclear Medicine and Radiopharmaceuticals Consumption Forecast (2022-2028)

• 13.5.2 Colombia Nuclear Medicine and Radiopharmaceuticals Consumption Forecast (2022-2028)

• 13.5.3 Chile Nuclear Medicine and Radiopharmaceuticals Consumption Forecast (2022-2028)

• 13.5.4 Argentina Nuclear Medicine and Radiopharmaceuticals Consumption Forecast (2022-2028)

• 13.5.5 Venezuela Nuclear Medicine and Radiopharmaceuticals Consumption Forecast (2022-2028)

• 13.5.6 Peru Nuclear Medicine and Radiopharmaceuticals Consumption Forecast (2022-2028)

• 13.5.7 Puerto Rico Nuclear Medicine and Radiopharmaceuticals Consumption Forecast (2022-2028)

• 13.5.8 Ecuador Nuclear Medicine and Radiopharmaceuticals Consumption Forecast (2022-2028)

• 13.6 GCC Consumption Analysis

• 13.6.1 Bahrain Nuclear Medicine and Radiopharmaceuticals Consumption Forecast (2022-2028)

• 13.6.2 Kuwait Nuclear Medicine and Radiopharmaceuticals Consumption Forecast (2022-2028)

• 13.6.3 Oman Nuclear Medicine and Radiopharmaceuticals Consumption Forecast (2022-2028)

• 13.6.4 Qatar Nuclear Medicine and Radiopharmaceuticals Consumption Forecast (2022-2028)

• 13.6.5 Saudi Arabia Nuclear Medicine and Radiopharmaceuticals Consumption Forecast (2022-2028)

• 13.6.6 United Arab Emirates Nuclear Medicine and Radiopharmaceuticals Consumption Forecast (2022-2028)

• 13.7 Africa Consumption Analysis

• 13.7.1 Nigeria Nuclear Medicine and Radiopharmaceuticals Consumption Forecast (2022-2028)

• 13.7.2 South Africa Nuclear Medicine and Radiopharmaceuticals Consumption Forecast (2022-2028)

• 13.7.3 Egypt Nuclear Medicine and Radiopharmaceuticals Consumption Forecast (2022-2028)

• 13.7.4 Algeria Nuclear Medicine and Radiopharmaceuticals Consumption Forecast (2022-2028)

• 13.8 Oceania Consumption Analysis

• 13.8.1 Australia Nuclear Medicine and Radiopharmaceuticals Consumption Forecast (2022-2028)

• 13.8.2 New Zealand Nuclear Medicine and Radiopharmaceuticals Consumption Forecast (2022-2028)

14 Conclusions

The List of Tables and Figures

• Table Definition of Nuclear Medicine and Radiopharmaceuticals

• Figure of Nuclear Medicine and Radiopharmaceuticals Picture

• Table Global Nuclear Medicine and Radiopharmaceuticals Import by Region (Top 10 Countries) (2017-2028)

• Table Global Nuclear Medicine and Radiopharmaceuticals Export by Region (Top 10 Countries) (2017-2028)

• Figure Global Diagnostic Radioisotopes Consumption and Growth Rate (2017-2022)

• Figure Global Therapeutic Radioisotopes Consumption and Growth Rate (2017-2022)

• Figure Global Oncology Consumption and Growth Rate (2017-2022)

• Figure Global Cardiology Consumption and Growth Rate (2017-2022)

• Figure Global Other Consumption and Growth Rate (2017-2022)

• Figure Global Nuclear Medicine and Radiopharmaceuticals Consumption by Country (2017-2022)

• Table North America Nuclear Medicine and Radiopharmaceuticals Consumption by Country (2017-2022)

• Figure United States Nuclear Medicine and Radiopharmaceuticals Consumption and Growth Rate (2017-2022)

• Figure Canada Nuclear Medicine and Radiopharmaceuticals Consumption and Growth Rate (2017-2022)

• Figure Mexico Nuclear Medicine and Radiopharmaceuticals Consumption and Growth Rate (2017-2022)

• Table Europe Nuclear Medicine and Radiopharmaceuticals Consumption by Country (2017-2022)

• Figure Germany Nuclear Medicine and Radiopharmaceuticals Consumption and Growth Rate (2017-2022)

• Figure UK Nuclear Medicine and Radiopharmaceuticals Consumption and Growth Rate (2017-2022)

• Figure Spain Nuclear Medicine and Radiopharmaceuticals Consumption and Growth Rate (2017-2022)

• Figure Belgium Nuclear Medicine and Radiopharmaceuticals Consumption and Growth Rate (2017-2022)

• Figure France Nuclear Medicine and Radiopharmaceuticals Consumption and Growth Rate (2017-2022)

• Figure Italy Nuclear Medicine and Radiopharmaceuticals Consumption and Growth Rate (2017-2022)

• Figure Denmark Nuclear Medicine and Radiopharmaceuticals Consumption and Growth Rate (2017-2022)

• Figure Finland Nuclear Medicine and Radiopharmaceuticals Consumption and Growth Rate (2017-2022)

• Figure Norway Nuclear Medicine and Radiopharmaceuticals Consumption and Growth Rate (2017-2022)

• Figure Sweden Nuclear Medicine and Radiopharmaceuticals Consumption and Growth Rate (2017-2022)

• Figure Poland Nuclear Medicine and Radiopharmaceuticals Consumption and Growth Rate (2017-2022)

• Figure Russia Nuclear Medicine and Radiopharmaceuticals Consumption and Growth Rate (2017-2022)

• Figure Turkey Nuclear Medicine and Radiopharmaceuticals Consumption and Growth Rate (2017-2022)

• Table APAC Nuclear Medicine and Radiopharmaceuticals Consumption by Country (2017-2022)

• Figure China Nuclear Medicine and Radiopharmaceuticals Consumption and Growth Rate (2017-2022)

• Figure Japan Nuclear Medicine and Radiopharmaceuticals Consumption and Growth Rate (2017-2022)

• Figure India Nuclear Medicine and Radiopharmaceuticals Consumption and Growth Rate (2017-2022)

• Figure South Korea Nuclear Medicine and Radiopharmaceuticals Consumption and Growth Rate (2017-2022)

• Figure Pakistan Nuclear Medicine and Radiopharmaceuticals Consumption and Growth Rate (2017-2022)

• Figure Bangladesh Nuclear Medicine and Radiopharmaceuticals Consumption and Growth Rate (2017-2022)

• Figure Indonesia Nuclear Medicine and Radiopharmaceuticals Consumption and Growth Rate (2017-2022)

• Figure Thailand Nuclear Medicine and Radiopharmaceuticals Consumption and Growth Rate (2017-2022)

• Figure Singapore Nuclear Medicine and Radiopharmaceuticals Consumption and Growth Rate (2017-2022)

• Figure Malaysia Nuclear Medicine and Radiopharmaceuticals Consumption and Growth Rate (2017-2022)

• Figure Philippines Nuclear Medicine and Radiopharmaceuticals Consumption and Growth Rate (2017-2022)

• Figure Vietnam Nuclear Medicine and Radiopharmaceuticals Consumption and Growth Rate (2017-2022)

• Table South America Nuclear Medicine and Radiopharmaceuticals Consumption by Country (2017-2022)

• Figure Brazil Nuclear Medicine and Radiopharmaceuticals Consumption and Growth Rate (2017-2022)

• Figure Colombia Nuclear Medicine and Radiopharmaceuticals Consumption and Growth Rate (2017-2022)

• Figure Chile Nuclear Medicine and Radiopharmaceuticals Consumption and Growth Rate (2017-2022)

• Figure Argentina Nuclear Medicine and Radiopharmaceuticals Consumption and Growth Rate (2017-2022)

• Figure Venezuela Nuclear Medicine and Radiopharmaceuticals Consumption and Growth Rate (2017-2022)

• Figure Peru Nuclear Medicine and Radiopharmaceuticals Consumption and Growth Rate (2017-2022)

• Figure Puerto Rico Nuclear Medicine and Radiopharmaceuticals Consumption and Growth Rate (2017-2022)

• Figure Ecuador Nuclear Medicine and Radiopharmaceuticals Consumption and Growth Rate (2017-2022)

• Table GCC Nuclear Medicine and Radiopharmaceuticals Consumption by Country (2017-2022)

• Figure Bahrain Nuclear Medicine and Radiopharmaceuticals Consumption and Growth Rate (2017-2022)

• Figure Kuwait Nuclear Medicine and Radiopharmaceuticals Consumption and Growth Rate (2017-2022)

• Figure Oman Nuclear Medicine and Radiopharmaceuticals Consumption and Growth Rate (2017-2022)

• Figure Qatar Nuclear Medicine and Radiopharmaceuticals Consumption and Growth Rate (2017-2022)

• Figure Saudi Arabia Nuclear Medicine and Radiopharmaceuticals Consumption and Growth Rate (2017-2022)

• Figure United Arab Emirates Nuclear Medicine and Radiopharmaceuticals Consumption and Growth Rate (2017-2022)

• Table Africa Nuclear Medicine and Radiopharmaceuticals Consumption by Country (2017-2022)

• Figure Nigeria Nuclear Medicine and Radiopharmaceuticals Consumption and Growth Rate (2017-2022)

• Figure South Africa Nuclear Medicine and Radiopharmaceuticals Consumption and Growth Rate (2017-2022)

• Figure Egypt Nuclear Medicine and Radiopharmaceuticals Consumption and Growth Rate (2017-2022)

• Figure Algeria Nuclear Medicine and Radiopharmaceuticals Consumption and Growth Rate (2017-2022)

• Table Oceania Nuclear Medicine and Radiopharmaceuticals Consumption by Country (2017-2022)

• Figure Australia Nuclear Medicine and Radiopharmaceuticals Consumption and Growth Rate (2017-2022)

• Figure New Zealand Nuclear Medicine and Radiopharmaceuticals Consumption and Growth Rate (2017-2022)

• Table Navidea Company Details

• Table Navidea Nuclear Medicine and Radiopharmaceuticals Sales, Price, Value and Gross Profit (2017-2022)

• Table Navidea Nuclear Medicine and Radiopharmaceuticals Main Business and Markets Served

• Table Navidea Nuclear Medicine and Radiopharmaceuticals Product Portfolio

• Table Mallinckrodt Company Details

• Table Mallinckrodt Nuclear Medicine and Radiopharmaceuticals Sales, Price, Value and Gross Profit (2017-2022)

• Table Mallinckrodt Nuclear Medicine and Radiopharmaceuticals Main Business and Markets Served

• Table Mallinckrodt Nuclear Medicine and Radiopharmaceuticals Product Portfolio

• Table Dongcheng Company Details

• Table Dongcheng Nuclear Medicine and Radiopharmaceuticals Sales, Price, Value and Gross Profit (2017-2022)

• Table Dongcheng Nuclear Medicine and Radiopharmaceuticals Main Business and Markets Served

• Table Dongcheng Nuclear Medicine and Radiopharmaceuticals Product Portfolio

• Table Triad Isotopes Company Details

• Table Triad Isotopes Nuclear Medicine and Radiopharmaceuticals Sales, Price, Value and Gross Profit (2017-2022)

• Table Triad Isotopes Nuclear Medicine and Radiopharmaceuticals Main Business and Markets Served

• Table Triad Isotopes Nuclear Medicine and Radiopharmaceuticals Product Portfolio

• Table Lantheus Company Details

• Table Lantheus Nuclear Medicine and Radiopharmaceuticals Sales, Price, Value and Gross Profit (2017-2022)

• Table Lantheus Nuclear Medicine and Radiopharmaceuticals Main Business and Markets Served

• Table Lantheus Nuclear Medicine and Radiopharmaceuticals Product Portfolio

• Table Advanced Accelerator Applications Company Details

• Table Advanced Accelerator Applications Nuclear Medicine and Radiopharmaceuticals Sales, Price, Value and Gross Profit (2017-2022)

• Table Advanced Accelerator Applications Nuclear Medicine and Radiopharmaceuticals Main Business and Markets Served

• Table Advanced Accelerator Applications Nuclear Medicine and Radiopharmaceuticals Product Portfolio

• Table Bayer Company Details

• Table Bayer Nuclear Medicine and Radiopharmaceuticals Sales, Price, Value and Gross Profit (2017-2022)

• Table Bayer Nuclear Medicine and Radiopharmaceuticals Main Business and Markets Served

• Table Bayer Nuclear Medicine and Radiopharmaceuticals Product Portfolio

• Table Bracco Imaging Company Details

• Table Bracco Imaging Nuclear Medicine and Radiopharmaceuticals Sales, Price, Value and Gross Profit (2017-2022)

• Table Bracco Imaging Nuclear Medicine and Radiopharmaceuticals Main Business and Markets Served

• Table Bracco Imaging Nuclear Medicine and Radiopharmaceuticals Product Portfolio

• Table Nordion Company Details

• Table Nordion Nuclear Medicine and Radiopharmaceuticals Sales, Price, Value and Gross Profit (2017-2022)

• Table Nordion Nuclear Medicine and Radiopharmaceuticals Main Business and Markets Served

• Table Nordion Nuclear Medicine and Radiopharmaceuticals Product Portfolio

• Table GE Healthcare Company Details

• Table GE Healthcare Nuclear Medicine and Radiopharmaceuticals Sales, Price, Value and Gross Profit (2017-2022)

• Table GE Healthcare Nuclear Medicine and Radiopharmaceuticals Main Business and Markets Served

• Table GE Healthcare Nuclear Medicine and Radiopharmaceuticals Product Portfolio

• Table SIEMENS Company Details

• Table SIEMENS Nuclear Medicine and Radiopharmaceuticals Sales, Price, Value and Gross Profit (2017-2022)

• Table SIEMENS Nuclear Medicine and Radiopharmaceuticals Main Business and Markets Served

• Table SIEMENS Nuclear Medicine and Radiopharmaceuticals Product Portfolio

• Table IBA Group Company Details

• Table IBA Group Nuclear Medicine and Radiopharmaceuticals Sales, Price, Value and Gross Profit (2017-2022)

• Table IBA Group Nuclear Medicine and Radiopharmaceuticals Main Business and Markets Served

• Table IBA Group Nuclear Medicine and Radiopharmaceuticals Product Portfolio

• Table Eli Lilly Company Details

• Table Eli Lilly Nuclear Medicine and Radiopharmaceuticals Sales, Price, Value and Gross Profit (2017-2022)

• Table Eli Lilly Nuclear Medicine and Radiopharmaceuticals Main Business and Markets Served

• Table Eli Lilly Nuclear Medicine and Radiopharmaceuticals Product Portfolio

• Table China Isotope & Radiation Company Details

• Table China Isotope & Radiation Nuclear Medicine and Radiopharmaceuticals Sales, Price, Value and Gross Profit (2017-2022)

• Table China Isotope & Radiation Nuclear Medicine and Radiopharmaceuticals Main Business and Markets Served

• Table China Isotope & Radiation Nuclear Medicine and Radiopharmaceuticals Product Portfolio

• Table Jubilant Pharma Company Details

• Table Jubilant Pharma Nuclear Medicine and Radiopharmaceuticals Sales, Price, Value and Gross Profit (2017-2022)

• Table Jubilant Pharma Nuclear Medicine and Radiopharmaceuticals Main Business and Markets Served

• Table Jubilant Pharma Nuclear Medicine and Radiopharmaceuticals Product Portfolio

• Figure Global Diagnostic Radioisotopes Consumption Forecast and Growth Rate (2022-2028)

• Figure Global Therapeutic Radioisotopes Consumption Forecast and Growth Rate (2022-2028)

• Figure Global Oncology Consumption Forecast and Growth Rate (2022-2028)

• Figure Global Cardiology Consumption Forecast and Growth Rate (2022-2028)

• Figure Global Other Consumption Forecast and Growth Rate (2022-2028)

• Figure Global Nuclear Medicine and Radiopharmaceuticals Consumption Forecast by Country (2022-2028)

• Table North America Nuclear Medicine and Radiopharmaceuticals Consumption Forecast by Country (2022-2028)

• Figure United States Nuclear Medicine and Radiopharmaceuticals Consumption Forecast and Growth Rate (2022-2028)

• Figure Canada Nuclear Medicine and Radiopharmaceuticals Consumption Forecast and Growth Rate (2022-2028)

• Figure Mexico Nuclear Medicine and Radiopharmaceuticals Consumption Forecast and Growth Rate (2022-2028)

• Table Europe Nuclear Medicine and Radiopharmaceuticals Consumption Forecast by Country (2022-2028)

• Figure Germany Nuclear Medicine and Radiopharmaceuticals Consumption Forecast and Growth Rate (2022-2028)

• Figure UK Nuclear Medicine and Radiopharmaceuticals Consumption Forecast and Growth Rate (2022-2028)

• Figure Spain Nuclear Medicine and Radiopharmaceuticals Consumption Forecast and Growth Rate (2022-2028)

• Figure Belgium Nuclear Medicine and Radiopharmaceuticals Consumption Forecast and Growth Rate (2022-2028)

• Figure France Nuclear Medicine and Radiopharmaceuticals Consumption Forecast and Growth Rate (2022-2028)

• Figure Italy Nuclear Medicine and Radiopharmaceuticals Consumption Forecast and Growth Rate (2022-2028)

• Figure Denmark Nuclear Medicine and Radiopharmaceuticals Consumption Forecast and Growth Rate (2022-2028)

• Figure Finland Nuclear Medicine and Radiopharmaceuticals Consumption Forecast and Growth Rate (2022-2028)

• Figure Norway Nuclear Medicine and Radiopharmaceuticals Consumption Forecast and Growth Rate (2022-2028)

• Figure Sweden Nuclear Medicine and Radiopharmaceuticals Consumption Forecast and Growth Rate (2022-2028)

• Figure Poland Nuclear Medicine and Radiopharmaceuticals Consumption Forecast and Growth Rate (2022-2028)

• Figure Russia Nuclear Medicine and Radiopharmaceuticals Consumption Forecast and Growth Rate (2022-2028)

• Figure Turkey Nuclear Medicine and Radiopharmaceuticals Consumption Forecast and Growth Rate (2022-2028)

• Table APAC Nuclear Medicine and Radiopharmaceuticals Consumption Forecast by Country (2022-2028)

• Figure China Nuclear Medicine and Radiopharmaceuticals Consumption Forecast and Growth Rate (2022-2028)

• Figure Japan Nuclear Medicine and Radiopharmaceuticals Consumption Forecast and Growth Rate (2022-2028)

• Figure India Nuclear Medicine and Radiopharmaceuticals Consumption Forecast and Growth Rate (2022-2028)

• Figure South Korea Nuclear Medicine and Radiopharmaceuticals Consumption Forecast and Growth Rate (2022-2028)

• Figure Pakistan Nuclear Medicine and Radiopharmaceuticals Consumption Forecast and Growth Rate (2022-2028)

• Figure Bangladesh Nuclear Medicine and Radiopharmaceuticals Consumption Forecast and Growth Rate (2022-2028)

• Figure Indonesia Nuclear Medicine and Radiopharmaceuticals Consumption Forecast and Growth Rate (2022-2028)

• Figure Thailand Nuclear Medicine and Radiopharmaceuticals Consumption Forecast and Growth Rate (2022-2028)

• Figure Singapore Nuclear Medicine and Radiopharmaceuticals Consumption Forecast and Growth Rate (2022-2028)

• Figure Malaysia Nuclear Medicine and Radiopharmaceuticals Consumption Forecast and Growth Rate (2022-2028)

• Figure Philippines Nuclear Medicine and Radiopharmaceuticals Consumption Forecast and Growth Rate (2022-2028)

• Figure Vietnam Nuclear Medicine and Radiopharmaceuticals Consumption Forecast and Growth Rate (2022-2028)

• Table South America Nuclear Medicine and Radiopharmaceuticals Consumption Forecast by Country (2022-2028)

• Figure Brazil Nuclear Medicine and Radiopharmaceuticals Consumption Forecast and Growth Rate (2022-2028)

• Figure Colombia Nuclear Medicine and Radiopharmaceuticals Consumption Forecast and Growth Rate (2022-2028)

• Figure Chile Nuclear Medicine and Radiopharmaceuticals Consumption Forecast and Growth Rate (2022-2028)

• Figure Argentina Nuclear Medicine and Radiopharmaceuticals Consumption Forecast and Growth Rate (2022-2028)

• Figure Venezuela Nuclear Medicine and Radiopharmaceuticals Consumption Forecast and Growth Rate (2022-2028)

• Figure Peru Nuclear Medicine and Radiopharmaceuticals Consumption Forecast and Growth Rate (2022-2028)

• Figure Puerto Rico Nuclear Medicine and Radiopharmaceuticals Consumption Forecast and Growth Rate (2022-2028)

• Figure Ecuador Nuclear Medicine and Radiopharmaceuticals Consumption Forecast and Growth Rate (2022-2028)

• Table GCC Nuclear Medicine and Radiopharmaceuticals Consumption Forecast by Country (2022-2028)

• Figure Bahrain Nuclear Medicine and Radiopharmaceuticals Consumption Forecast and Growth Rate (2022-2028)

• Figure Kuwait Nuclear Medicine and Radiopharmaceuticals Consumption Forecast and Growth Rate (2022-2028)

• Figure Oman Nuclear Medicine and Radiopharmaceuticals Consumption Forecast and Growth Rate (2022-2028)

• Figure Qatar Nuclear Medicine and Radiopharmaceuticals Consumption Forecast and Growth Rate (2022-2028)

• Figure Saudi Arabia Nuclear Medicine and Radiopharmaceuticals Consumption Forecast and Growth Rate (2022-2028)

• Figure United Arab Emirates Nuclear Medicine and Radiopharmaceuticals Consumption Forecast and Growth Rate (2022-2028)

• Table Africa Nuclear Medicine and Radiopharmaceuticals Consumption Forecast by Country (2022-2028)

• Figure Nigeria Nuclear Medicine and Radiopharmaceuticals Consumption Forecast and Growth Rate (2022-2028)

• Figure South Africa Nuclear Medicine and Radiopharmaceuticals Consumption Forecast and Growth Rate (2022-2028)

• Figure Egypt Nuclear Medicine and Radiopharmaceuticals Consumption Forecast and Growth Rate (2022-2028)

• Figure Algeria Nuclear Medicine and Radiopharmaceuticals Consumption Forecast and Growth Rate (2022-2028)

• Table Oceania Nuclear Medicine and Radiopharmaceuticals Consumption Forecast by Country (2022-2028)

• Figure Australia Nuclear Medicine and Radiopharmaceuticals Consumption Forecast and Growth Rate (2022-2028)

• Figure New Zealand Nuclear Medicine and Radiopharmaceuticals Consumption Forecast and Growth Rate (2022-2028)